These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16682709)

  • 81. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators.
    Antman EM
    Am Heart J; 1998 Jun; 135(6 Pt 3 Su):S353-60. PubMed ID: 9628449
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction.
    Melandri G; Vagnarelli F; Calabrese D; Semprini F; Nanni S; Branzi A
    Vasc Health Risk Manag; 2009; 5(1):249-56. PubMed ID: 19436656
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction.
    Cohen M; Antman EM; Gurfinkel E; Turpie AG; Furst J; Bigonzi F; Radley D
    Am J Cardiol; 2000 Sep; 86(5):553-6, A9. PubMed ID: 11009278
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy.
    Ray KK; Morrow DA; Gibson CM; Murphy S; Antman EM; Braunwald E
    Eur Heart J; 2005 Mar; 26(5):440-6. PubMed ID: 15673542
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction.
    Berkowitz SD; Stinnett S; Cohen M; Fromell GJ; Bigonzi F;
    Am J Cardiol; 2001 Dec; 88(11):1230-4. PubMed ID: 11728348
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.
    Antman EM; Cohen M; Radley D; McCabe C; Rush J; Premmereur J; Braunwald E
    Circulation; 1999 Oct; 100(15):1602-8. PubMed ID: 10517730
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy.
    Cohen M; Stinnett SS; Weatherley BD; Gurfinkel EP; Fromell GJ; Goodman SG; Fox KA; Califf RM
    Am Heart J; 2000 Jun; 139(6):962-70. PubMed ID: 10827375
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Low-molecular-weight heparin alone versus a combination of unfractionated heparin and low-molecular-weight heparin.
    Gurfinkel EP; Santopinto J; Bozovich GE; Quispe A; Strinna A; Mautner B
    Am Heart J; 2000 Jul; 140(1):E12-8. PubMed ID: 10874258
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction.
    Bassand JP; Cariou R; Grollier G; Kragten J; Wolf JE; Heyndrickx GR
    Semin Thromb Hemost; 1999; 25 Suppl 2():69-75. PubMed ID: 10440428
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials.
    Eikelboom JW; Quinlan DJ; Mehta SR; Turpie AG; Menown IB; Yusuf S
    Circulation; 2005 Dec; 112(25):3855-67. PubMed ID: 16344381
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.
    ; Van De Werf F; Adgey J; Ardissino D; Armstrong PW; Aylward P; Barbash G; Betriu A; Binbrek AS; Califf R; Diaz R; Fanebust R; Fox K; Granger C; Heikkilä J; Husted S; Jansky P; Langer A; Lupi E; Maseri A; Meyer J; Mlczoch J; Mocceti D; Myburgh D; Oto A; Paolasso E; Pehrsson K; Seabra-Gomes R; Soares-Piegas L; Sùgrue D; Tendera M; Topol E; Toutouzas P; Vahanian A; Verheugt F; Wallentin L; White H
    Lancet; 1999 Aug; 354(9180):716-22. PubMed ID: 10475182
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Tenecteplase for treatment of acute myocardial infarction.
    Turcasso NM; Nappi JM
    Ann Pharmacother; 2001 Oct; 35(10):1233-40. PubMed ID: 11675853
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide.
    Goodman SG; Fitchett D; Armstrong PW; Tan M; Langer A;
    Circulation; 2003 Jan; 107(2):238-44. PubMed ID: 12538422
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design.
    Cohen M; Maritz F; Gensini GF; Danchin N; Timerman A; Huber K; Gurfinkel EP; White H; Fox KA; Vittori L; Le-Louer V; Bigonzi F
    J Thromb Thrombolysis; 2000 Dec; 10(3):241-6. PubMed ID: 11122544
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Comparison of effectiveness of enoxaparin versus unfractionated heparin to reduce silent and clinically apparent acute myocardial infarction in patients presenting with non-ST-segment elevation acute coronary syndrome.
    Jolly S; Tan M; Mendelsohn A; Fitchett D; Armstrong PW; Langer A; Goodman SG
    Am J Cardiol; 2007 Jan; 99(2):186-8. PubMed ID: 17223416
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study.
    Bhatt DL; Lee BI; Casterella PJ; Pulsipher M; Rogers M; Cohen M; Corrigan VE; Ryan TJ; Breall JA; Moses JW; Eaton GM; Sklar MA; Lincoff AM;
    J Am Coll Cardiol; 2003 Jan; 41(1):20-5. PubMed ID: 12570939
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Enoxaparin: an update of its clinical use in the management of acute coronary syndromes.
    Ibbotson T; Goa KL
    Drugs; 2002; 62(9):1407-30. PubMed ID: 12076195
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Pharmacologic reperfusion therapy with indigenous tenecteplase in 15,222 patients with ST elevation myocardial infarction - the Indian Registry.
    Iyengar SS; Nair T; Hiremath JS; Jadhav U; Katyal VK; Kumbla D; Sathyamurthy I; Jain RK; Srinivasan M
    Indian Heart J; 2013; 65(4):436-41. PubMed ID: 23993004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.